Stifel reiterates Glaukos stock rating on strong iDose growth
Stifel reiterated a Buy rating and $190 price target for Glaukos (GKOS), citing strong iDose growth and positive payer mix results. GKOS shares have risen 94% over the past year. The company reported Q2 2026 revenue of $185.6M, up 49.5% YoY. Analysts have raised price targets, with Truist setting the highest at $215.
How this was made
The 30-second read
Why it matters
The new rating and target provide a clear actionable signal for traders seeking upside in GKOS.
Market read
Analyst upgrade with a higher price target creates immediate trading interest in GKOS.
What to watch
Potential competition from emerging ocular drug therapies not fully addressed.
Background
Stifel's reiteration follows a series of analyst upgrades after Glaukos reported strong Q2 revenue and iDose sales growth.
Ticker impact
Stifel reiterated a Buy rating and raised the price target to $190, citing strong iDose growth and recent sales beat.
likely upward pressure as investors price in the new $190 target versus current $165.60 price
The rating and target are fresh analyst actions; no other catalyst is mentioned.
Market effects
Positive outlook for ophthalmic device sector as iDose growth may boost peers.
U.S. biotech and medical device stocks could see modest gains.
Limited to U.S. listed medical device companies.
Counterpoint
The iDose growth may be unsustainable; valuation could be stretched at $190 target.
Key entities
- companyGlaukos Corporation
US-listed ophthalmic device maker (ticker GKOS).
- analystStifel
Equity research firm issuing the Buy rating and price target.
